Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Expected to Earn FY2024 Earnings of ($0.65) Per Share

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) – Equities research analysts at HC Wainwright issued their FY2024 earnings per share estimates for Lexicon Pharmaceuticals in a report issued on Monday, June 17th. HC Wainwright analyst J. Pantginis anticipates that the biopharmaceutical company will post earnings of ($0.65) per share for the year. HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Lexicon Pharmaceuticals’ current full-year earnings is ($0.72) per share.

Several other research firms have also recently commented on LXRX. Leerink Partnrs restated an “outperform” rating on shares of Lexicon Pharmaceuticals in a research note on Tuesday, April 30th. Needham & Company LLC restated a “hold” rating on shares of Lexicon Pharmaceuticals in a research note on Friday, May 3rd. StockNews.com upgraded Lexicon Pharmaceuticals to a “sell” rating in a research note on Thursday, June 6th. Finally, SVB Leerink began coverage on Lexicon Pharmaceuticals in a research note on Tuesday, April 30th. They set an “outperform” rating and a $5.00 price target for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, Lexicon Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $6.67.

Lexicon Pharmaceuticals Stock Performance

Lexicon Pharmaceuticals stock opened at $1.72 on Tuesday. Lexicon Pharmaceuticals has a 12 month low of $0.92 and a 12 month high of $3.73. The company has a debt-to-equity ratio of 0.35, a quick ratio of 15.56 and a current ratio of 15.58. The business has a 50 day simple moving average of $1.76 and a 200-day simple moving average of $1.88.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.02). Lexicon Pharmaceuticals had a negative net margin of 8,311.12% and a negative return on equity of 108.54%. The firm had revenue of $1.13 million during the quarter, compared to analysts’ expectations of $1.17 million.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Cantor Fitzgerald L. P. purchased a new position in Lexicon Pharmaceuticals in the fourth quarter worth $25,000. Principal Securities Inc. acquired a new stake in Lexicon Pharmaceuticals in the fourth quarter valued at $33,000. China Universal Asset Management Co. Ltd. grew its holdings in Lexicon Pharmaceuticals by 350.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 28,329 shares of the biopharmaceutical company’s stock valued at $43,000 after purchasing an additional 22,043 shares during the last quarter. RPO LLC acquired a new stake in Lexicon Pharmaceuticals in the fourth quarter valued at $49,000. Finally, Victory Capital Management Inc. grew its holdings in Lexicon Pharmaceuticals by 22.0% in the fourth quarter. Victory Capital Management Inc. now owns 32,187 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 5,813 shares during the last quarter. Hedge funds and other institutional investors own 74.70% of the company’s stock.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.